HRP20141001T1 - Farmaceutski sferoidi - Google Patents
Farmaceutski sferoidi Download PDFInfo
- Publication number
- HRP20141001T1 HRP20141001T1 HRP20141001TT HRP20141001T HRP20141001T1 HR P20141001 T1 HRP20141001 T1 HR P20141001T1 HR P20141001T T HRP20141001T T HR P20141001TT HR P20141001 T HRP20141001 T HR P20141001T HR P20141001 T1 HRP20141001 T1 HR P20141001T1
- Authority
- HR
- Croatia
- Prior art keywords
- agents
- spheroids
- water
- matrix
- pharmaceutical preparation
- Prior art date
Links
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 18
- 239000011159 matrix material Substances 0.000 claims 17
- -1 anti -diabetics Substances 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 229940075507 glyceryl monostearate Drugs 0.000 claims 9
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 9
- 239000011248 coating agent Substances 0.000 claims 7
- 238000000576 coating method Methods 0.000 claims 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 6
- 235000010980 cellulose Nutrition 0.000 claims 6
- 229920002678 cellulose Polymers 0.000 claims 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 6
- 238000005563 spheronization Methods 0.000 claims 6
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000011230 binding agent Substances 0.000 claims 5
- 229960002738 hydromorphone hydrochloride Drugs 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- 239000000080 wetting agent Substances 0.000 claims 5
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 4
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 4
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 4
- 229960003406 levorphanol Drugs 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 229920003176 water-insoluble polymer Polymers 0.000 claims 4
- 229920003169 water-soluble polymer Polymers 0.000 claims 4
- 239000001993 wax Substances 0.000 claims 3
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 claims 2
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims 2
- LGFMXOTUSSVQJV-NEYUFSEYSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;1-[(3,4-dimethoxyphenyl)methyl]-6 Chemical compound Cl.Cl.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 LGFMXOTUSSVQJV-NEYUFSEYSA-N 0.000 claims 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 2
- IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 2
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 2
- 229940124091 Keratolytic Drugs 0.000 claims 2
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 2
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 2
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims 2
- 239000008896 Opium Substances 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 239000003741 agents affecting lipid metabolism Substances 0.000 claims 2
- 229960001391 alfentanil Drugs 0.000 claims 2
- KGYFOSCXVAXULR-UHFFFAOYSA-N allylprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1CC=C KGYFOSCXVAXULR-UHFFFAOYSA-N 0.000 claims 2
- 229950004361 allylprodine Drugs 0.000 claims 2
- 229960001349 alphaprodine Drugs 0.000 claims 2
- UVAZQQHAVMNMHE-XJKSGUPXSA-N alphaprodine Chemical compound C=1C=CC=CC=1[C@@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-XJKSGUPXSA-N 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 2
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 claims 2
- 229960002512 anileridine Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 230000000507 anthelmentic effect Effects 0.000 claims 2
- 239000000921 anthelmintic agent Substances 0.000 claims 2
- 229940124339 anthelmintic agent Drugs 0.000 claims 2
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000004004 anti-anginal agent Substances 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 2
- 230000003556 anti-epileptic effect Effects 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 230000003262 anti-osteoporosis Effects 0.000 claims 2
- 229940124345 antianginal agent Drugs 0.000 claims 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- 239000002255 antigout agent Substances 0.000 claims 2
- 229960002708 antigout preparations Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000003430 antimalarial agent Substances 0.000 claims 2
- 229940125684 antimigraine agent Drugs 0.000 claims 2
- 239000002282 antimigraine agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 239000003904 antiprotozoal agent Substances 0.000 claims 2
- 239000003200 antithyroid agent Substances 0.000 claims 2
- 229940043671 antithyroid preparations Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- FLKWNFFCSSJANB-UHFFFAOYSA-N bezitramide Chemical compound O=C1N(C(=O)CC)C2=CC=CC=C2N1C(CC1)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 FLKWNFFCSSJANB-UHFFFAOYSA-N 0.000 claims 2
- 229960004611 bezitramide Drugs 0.000 claims 2
- 229960001736 buprenorphine Drugs 0.000 claims 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 2
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 2
- 229960001113 butorphanol Drugs 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 229960004126 codeine Drugs 0.000 claims 2
- 239000002475 cognitive enhancer Substances 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 229950002213 cyclazocine Drugs 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims 2
- 229960003701 dextromoramide Drugs 0.000 claims 2
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 2
- 229960003461 dezocine Drugs 0.000 claims 2
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- RXTHKWVSXOIHJS-UHFFFAOYSA-N diampromide Chemical compound C=1C=CC=CC=1N(C(=O)CC)CC(C)N(C)CCC1=CC=CC=C1 RXTHKWVSXOIHJS-UHFFFAOYSA-N 0.000 claims 2
- 229950001059 diampromide Drugs 0.000 claims 2
- 229960000920 dihydrocodeine Drugs 0.000 claims 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 2
- RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims 2
- 229950011187 dimenoxadol Drugs 0.000 claims 2
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 2
- CANBGVXYBPOLRR-UHFFFAOYSA-N dimethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)C)C1=CC=CS1 CANBGVXYBPOLRR-UHFFFAOYSA-N 0.000 claims 2
- 229950005563 dimethylthiambutene Drugs 0.000 claims 2
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 2
- 229960002500 dipipanone Drugs 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- MORSAEFGQPDBKM-UHFFFAOYSA-N ethylmethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)CC)C1=CC=CS1 MORSAEFGQPDBKM-UHFFFAOYSA-N 0.000 claims 2
- 229950006111 ethylmethylthiambutene Drugs 0.000 claims 2
- 229960004578 ethylmorphine Drugs 0.000 claims 2
- 238000001125 extrusion Methods 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 229940125695 gastrointestinal agent Drugs 0.000 claims 2
- 239000004083 gastrointestinal agent Substances 0.000 claims 2
- 239000003163 gonadal steroid hormone Substances 0.000 claims 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 2
- 229960000240 hydrocodone Drugs 0.000 claims 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 2
- 229960001410 hydromorphone Drugs 0.000 claims 2
- WTJBNMUWRKPFRS-UHFFFAOYSA-N hydroxypethidine Chemical compound C=1C=CC(O)=CC=1C1(C(=O)OCC)CCN(C)CC1 WTJBNMUWRKPFRS-UHFFFAOYSA-N 0.000 claims 2
- 229950008496 hydroxypethidine Drugs 0.000 claims 2
- 239000003326 hypnotic agent Substances 0.000 claims 2
- 230000000147 hypnotic effect Effects 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 239000004041 inotropic agent Substances 0.000 claims 2
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 2
- 229950009272 isomethadone Drugs 0.000 claims 2
- 230000001530 keratinolytic effect Effects 0.000 claims 2
- 239000003410 keratolytic agent Substances 0.000 claims 2
- 229960003029 ketobemidone Drugs 0.000 claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 2
- 229950010274 lofentanil Drugs 0.000 claims 2
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 2
- 229940041033 macrolides Drugs 0.000 claims 2
- 229960000365 meptazinol Drugs 0.000 claims 2
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 2
- 229950009131 metazocine Drugs 0.000 claims 2
- YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- NPZXCTIHHUUEEJ-CMKMFDCUSA-N metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 claims 2
- 229950006080 metopon Drugs 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 2
- 229940035363 muscle relaxants Drugs 0.000 claims 2
- 239000003158 myorelaxant agent Substances 0.000 claims 2
- 229960000805 nalbuphine Drugs 0.000 claims 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 2
- 229960000938 nalorphine Drugs 0.000 claims 2
- 229960004127 naloxone Drugs 0.000 claims 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 2
- 229960003086 naltrexone Drugs 0.000 claims 2
- 229960004300 nicomorphine Drugs 0.000 claims 2
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 2
- 229950011519 norlevorphanol Drugs 0.000 claims 2
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 2
- 229960004013 normethadone Drugs 0.000 claims 2
- 229950006134 normorphine Drugs 0.000 claims 2
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims 2
- 229950007418 norpipanone Drugs 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 229960001027 opium Drugs 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 229960005118 oxymorphone Drugs 0.000 claims 2
- 229960003294 papaveretum Drugs 0.000 claims 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 2
- 229960005301 pentazocine Drugs 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 claims 2
- 229960000897 phenazocine Drugs 0.000 claims 2
- CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims 2
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 2
- 229960004315 phenoperidine Drugs 0.000 claims 2
- PXXKIYPSXYFATG-UHFFFAOYSA-N piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 claims 2
- 229950006445 piminodine Drugs 0.000 claims 2
- 239000002491 polymer binding agent Substances 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 2
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 claims 2
- 229950003779 propiram Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940125723 sedative agent Drugs 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 238000007873 sieving Methods 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 2
- 229960004739 sufentanil Drugs 0.000 claims 2
- 229960001402 tilidine Drugs 0.000 claims 2
- 229960004380 tramadol Drugs 0.000 claims 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940096529 carboxypolymethylene Drugs 0.000 claims 1
- GPZLDQAEBHTMPG-UHFFFAOYSA-N clonitazene Chemical compound N=1C2=CC([N+]([O-])=O)=CC=C2N(CCN(CC)CC)C=1CC1=CC=C(Cl)C=C1 GPZLDQAEBHTMPG-UHFFFAOYSA-N 0.000 claims 1
- 229950001604 clonitazene Drugs 0.000 claims 1
- 235000004626 essential fatty acids Nutrition 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- ZXWAUWBYASJEOE-UHFFFAOYSA-N proheptazine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCCN(C)CC1C ZXWAUWBYASJEOE-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (36)
1. Farmaceutski preparat koji sadrži sferoide, pri čemu su sferoidi u obliku matriksa koji sadrži, kao pomoćno sredstvo za sferonizaciju, između 20 i 95% (tež./tež.) gliceril monostearata, postoci prema težini su zasnovani na težini cijele jezgre sferoida, i polimerno vezivno sredstvo u odsustvu mikrokristalne celuloze.
2. Farmaceutski preparat prema patentnom zahtjevu 1 naznačen time što matriks dalje sadrži sredstvo za vlaženje.
3. Farmaceutski preparat prema patentnom zahtjevu 2 naznačen time što je sredstvo za vlaženje polisorbat 80.
4. Farmaceutski preparat prema bilo kojem od prethodnih patentnih zahtjeva naznačen time što je najmanje jedan terapeutski aktivni sastojak sadržan u matriksu.
5. Farmaceutski preparat prema patentnom zahtjevu 4 naznačen time što je/su terapeutski aktivni sastojak (sastojci) izabrani od analgetika, sredstava protiv angine, antiaritmika, anti-bakterijskih sredstava, sredstava protiv benigne hipertrofije prostate, anti-koagulanata, anti-depresiva, anti-dijabetika, antiepileptika, anti-gljivičnih sredstava, sredstava protiv gihta, antihipertenzivnih sredstava, anti-inflamatornih sredstava, sredstava protiv malarije, sredstava protiv migrene, anti-muskarinskih sredstava, anti-neoplastičnih sredstava, sredstava protiv debljine, sredstava protiv osteoporoze, sredstava protiv parkinsonizma, sredstava protiv protozoa, anti-tiroidnih sredstava, sredstava protiv urinarne inkontinencije, anti-virusnih sredstava, antelmintika, anksiolitičkih sredstava, beta-blokatora, kardijalnih inotropnih sredstava, sredstava za pojačanje kognicije, kortikosteroida, inhibitora cox-2, diuretika, sredstava za poboljšanje erektilne disfunkcije, esencijalnijh i ne-esencijalnih masnih kiselina, gastrointestinalnih sredstava, antagonista receptora za histamin, hipnotika, imunosupresanata, keratolitika, inhibitora leukotriena, sredstava za regulaciju lipida, makrolida; relaksanata mišića, neuroleptika, prehrambenih sredstava, opioida, inhibitora proteaze, sedativa, spolnih hormona i stimulanata.
6. Farmaceutski preparat prema patentnom zahtjevu 5 naznačen time što sadrži terapeutski aktivni sastojak opioid izabran od alfentanila, alilprodina, alfaprodina, anileridina, benzilmorfina, bezitramida, buprenorfina, butorfanola, klonitazena, kodeina, ciklazocina, dezomorpina, dekstromoramida, dezocina, diamorfina, diampromida, dihidrokodeina, dihidromorfina, dimenoksadola, dimefeptanola, dimetiltiambutena, dioksiafetil butirata, dipipanona, eptazocina, etoheptazina, etilmetiltiambutena, etilmorfina, etonitazena, fentanila, hidrokodona, hidromorfona, hidroksipetidina, izometadona, ketobemidona, levalorfana, levorfanola, levofenacilmorfana, lofentanila, meperidina, meptazinola, metazocina, metadona, metopona, morfina, nalbufina, naloksona, naltreksona, narceina, nikomorfina, norlevorfanola, normetadona, nalorfina, normorfina, norpipanona, opijuma, oksikodona, oksimorfona, papaveretuma, pentazocina, fenadoksona, fenomorfana, fenazocina, fenoperidina, piminodina, piritramida, profeptazina, promedola, properidina, propirama, propoksifena, sufentanila, tramadola i tilidina, i njihove farmaceutski prihvatljive soli i kompleksa.
7. Farmaceutski preparat prema patentnom zahtjevu 6 naznačen time što opioid je hidromorfon hidroklorid i matriks ne sadrži ili značajno ne sadrži mikrokristalnu celulozu.
8. Farmaceutski preparat prema bilo kojem od prethodnog patentnog zahtjeva koji sadrži kapsulu koja sadrži veći broj navedenih sferoida i koji je pogodan za oralnu primjenu.
9. Farmaceutski preparat u obliku tablete koja sadrži sferoide prema bilo kojem od patentnih zahtjeva 1 do 7 i inertne punitelje za tabletiranje.
10. Postupak za pripremu sferoida u obliku matriksa koji sadrži, kao pomoćno sredstvo za sferonizaciju, između 20 i 95% (tež./tež.) gliceril monostearata, pri čemu su postoci prema težini zasnovani na težini cijele jezgre sferoida, i polimerno vezivno sredstvo u odsustvu mikrokristalne celuloze, pri čemu taj postupak sadrži korake:
a) formiranja ekstrudabilne vlažne mase koja sadrži gliceril monostearat, vodu i polimerno vezivno sredstvo;
b) ekstruzije vlažne mase;
c) sferonizacije ekstrudata;
d) sušenja i prosijavanja rezultirajućih sferoida; i
e) izborno oblaganja osušenih sferoida,
pri čemu se postupak izvodi u komercijalnim razmjerima.
11. Obloženi sferoidi pogodni za uporabu u farmaceutskom preparatu koji sadrži jezgru matriksa koje sadrži kao pomoćno sredstvo za sferonizaciju između 30 i 95% (tež./tež.) gliceril monostearata, pri čemu su % (tež./tež.) zasnovani na težini neobloženih sferoida, i polimerno vezivno sredstvo, i omotač koji okružuje jezgru matriksa, pri čemu jezgra matriksa ne sadrži ili značajno ne sadrži mikrokristalnu celulozu.
12. Sferoidi prema patentnom zahtjevu 11 naznačeni time što matriks dalje sadrži sredstvo za vlaženje.
13. Sferoidi prema patentnom zahtjevu 12 naznačeni time što sredstvo za vlaženje je polisorbat 80.
14. Sferoidi prema bilo kojem od patentnih zahtjeva 11 do 13 naznačeni time što omotač je film omotač koji nema ili značajno nema osobinu kontrole oslobađanja.
15. Sferoidi prema bilo kojem od patentnih zahtjeva 11 do 13 naznačeni time što omotač je omotač sa kontroliranim oslobađanjem.
16. Sferoidi prema patentnom zahtjevu 15 naznačeni time što omotač sadrži jedan ili više materijala izabranih od vosaka netopljivih u vodi, polimera netopljivih u vodi, polimera topljivih u vodi, celuloza netopljivih u vodi i celuloza topljivih u vodi.
17. Sferoidi prema patentnom zahtjevu 16 naznačeni time što polimeri netopljivi u vodi sadrže polimetakrilate.
18. Sferoidi prema patentnom zahtjevu 16 ili 17 naznačeni time što celuloze netopljive u vodi sadrže etilcelulozu.
19. Sferoidi prema patentnom zahtjevu 16, 17 ili 18 naznačeni time što polimeri topljivi u vodi sadrže polivinil pirolidon.
20. Sferoidi prema bilo kom od patentnih zahtjeva 16 do 19 naznačeni time što celuloze rastvorljive u vodi sadrže hidroksipropilmetil celulozu i hidroksipropil celulozu.
21. Sferoidi prema bilo kom od patentnih zahtjeva 11 do 20 naznačeni time što matriks sadrži od 50 do 95% tež./tež. gliceril monostearata.
22. Sferoidi prema patentnom zahtjevu 21 naznačeni time što matriks sadrži od 75 do 95% tež./tež. gliceril monostearata.
23. Sferoidi prema patentnom zahtjevu 22 naznačeni time što matriks sadrži od 90 do 95% tež./tež. gliceril monosterata.
24. Sferoidi prema bilo kom od patentnih zahtjeva 11 do 23 naznačeni time što je polimerno vezujuće sredstvo izabrano od polivinil pirolidona, karboksipolimetilen i akrilnih polimera.
25. Sferoidi prema bilo kom od patentnih zahtjeva 11 do 24 naznačeni time što matriks sadrži od 2 do 9% tež./tež. polivinil pirolidona.
26. Sferoidi prema patentnom zahtjevu 25 naznačeni time što matriks sadrži od 2.5% do 7.5% tež./tež. polivinil pirolidona.
27. Sferoidi prema patentnom zahtjevu 26 naznačeni time što matriks sadrži od 4% do 5% tež./tež. polivinil pirolidona.
28. Sferoidi prema bilo kom od patentnih zahtjeva 11 do 27 naznačeni time što je najmanje jedan terapeutski aktivan sastojak prisutan u matriksu.
29. Sferoidi prema patentnom zahtjevu 28 naznačeni time što je/su terapeutski aktivno sredstvo (sredstva) izabrana od analgetika, sredstava protiv angine, antiaritmika, anti-bakterijskih sredstava, sredstava protiv benigne hipertrofije prostate, anti-koagulanata, anti-depresiva, anti-dijabetika, antiepileptika, anti-gljivičnih sredstava, sredstava protiv gihta, antihipertenzivnih sredstava, anti-inflamatornih sredstava, sredstava protiv malarije, sredstava protiv migrene, anti-muskarinskih sredstava, anti-neoplastičnih sredstava, sredstava protiv gojaznosti, sredstava protiv osteoporoze, sredstava protiv parkinsonizma, sredstava protiv protozoa, anti-tiroidnih sredstava, sredstava protiv urinarne inkontinencije, anti-virusnih sredstava, antelmintika, anksiolitičkih sredstava, beta-blokatora, kardijačnih inotropnih sredstava, sredstava za pojačanje kognicije, kortikosteroida, inhibitora cox-2, diuretika, sredstava za poboljšanje erektilne disfunkcije, esencijalnijh i ne-esencijalnih masnih kiselina, gastrointestinalnih sredstava, antagonista receptora za histamin, hipnotika, imunosupresanata, keratolitika, inhibitora leukotriena, sredstava za regulaciju lipida, makrolida; relaksanata mišića, neuroleptika, nutricionih sredstava, opioida, inhibitora proteaze, sedativa, polnih hormona i stimulanata.
30. Sferoidi prema patentnom zahtjevu 29 naznačeni time što sadrže terapeutski aktivni sastojak kao opioid izabran od alfentanila, alilprodina, alfaprodina, anileridina, benzilmorfina, bezitramida, buprenorfina, butorfanola, klonitazena, kodeina, ciklazocina, dezomorpina, dekstromoramida, dezocina, diamorfina, diampromida, dihidrokodeina, dihidromorfina, dimenoksadola, dimefeptanola, dimetiltiambutena, dioksiafetil butirata, dipipanona, eptazocina, etoheptazina, etilmetiltiambutena, etilmorfina, etonitazena, fentanila, hidrokodona, hidromorfona, hidroksipetidina, izometadona, ketobemidona, levalorfana, levorfanola, levofenacilmorfana, lofentanila, meperidina, meptazinola, metazocina, metadona, metopona, morfina, nalbufina, naloksona, naltreksona, narceina, nikomorfina, norlevorfanola, normetadona, nalorfina, normorfina, norpipanona, opijuma, oksikodona, oksimorfona, papaveretuma, pentazocina, fenadoksona, fenomorfana, fenazocina, fenoperidina, piminodina, piritramida, profeptazina, promedola, properidina, propirama, propoksifena, sufentanila, tramadola i tilidina, i njihove farmaceutski prihvatljive soli i kompleksa.
31. Sferoidi prema patentnom zahtjevu 30 naznačeni time što opioid je hidromorfon hidrohlorid i matriks ne sadrži ili značajno ne sadrži mikrokristalnu celulozu.
32. Postupak za pripremu sferoida kao što je definiran u patentnom zahtjevu 11 naznačen time što sadrži korake:
a) formiranja ekstrudabilne vlažne mase koja sadrži gliceril monostearat, vodu i polimerno vezujuće sredstvo;
b) ekstruzije vlažne mase;
c) sferonizacije ekstrudata;
d) sušenja i prosejavanja rezultirajućih sferoida;
e) oblaganja osušenih sferoida.
33. Postupak prema patentnom zahtjevu 32, naznačen time što materijal za oblaganje sadrži jedan ili više materijala izabranih od voskova nerastvorljivih u vodi, polimera nerastvorljivih u vodi, polimera rastvorljivih u vodi, celuloza nerastvorljivih u vodi i celuloza rastvorljivih u vodi.
34. Sferoid koji sadrži, kao pomoćno sredstvo za sferonizaciju, gliceril monostearat i polimerno vezujuće sredstvo, i dalje sadrži hidromorfon hidrohlorid i izborno sredstvo za vlaženje, pri čemu sferoid ne sadrži ili značajno ne sadrži mikrokristalnu celulozu, i okružen je omotačem za kontrolirano oslobađanje koji sadrži jedan ili više materijala izabranih od vosokova nerastvorljivih u vodi, polimera nerastvorljivih u vodi i polimera rastvorljivih u vodi.
35. Farmaceutski oblik jedinične doze koji sadrži sferoide kao što su definirani u bilo kom od prethodnih patentnih zahtjeva, pri čemu oblik jedinične doze sadrži 2 mg, 4 mg, 8 mg, 16 mg, ili 24 mg hidromorfon hidrohlorida.
36. Farmaceutski oblik jedinične doze prema patentnom zahtjevu 35 koji sadrži 4 mg hidromorfon hidrohlorida i koji, kada se primjeni na zdrave subjekte u studiji jedne doze, daje srednju vrijednost Cmax i srednju vrednost AUC0-inf, za koje su 90% intervali povjerenja unutar ± 20% od 1.16 ng/ml i 10.35 ng.čas/ml, respektivno.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0605271A GB0605271D0 (en) | 2006-03-16 | 2006-03-16 | Pharmaceutical spheroids |
| GB0605542A GB0605542D0 (en) | 2006-03-20 | 2006-03-20 | Pharmaceutical Spheroids |
| GB0617272A GB0617272D0 (en) | 2006-09-04 | 2006-09-04 | Pharmaceutical spheroids |
| PCT/GB2007/050129 WO2007105016A1 (en) | 2006-03-16 | 2007-03-16 | Pharmaceutical spheroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141001T1 true HRP20141001T1 (hr) | 2014-12-05 |
Family
ID=38191129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141001TT HRP20141001T1 (hr) | 2006-03-16 | 2014-10-20 | Farmaceutski sferoidi |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9034373B2 (hr) |
| EP (1) | EP2001445B1 (hr) |
| JP (2) | JP5443768B2 (hr) |
| CY (1) | CY1115770T1 (hr) |
| DK (1) | DK2001445T3 (hr) |
| ES (1) | ES2516693T3 (hr) |
| HR (1) | HRP20141001T1 (hr) |
| ME (1) | ME02135B (hr) |
| PL (1) | PL2001445T3 (hr) |
| PT (1) | PT2001445E (hr) |
| RS (1) | RS53624B1 (hr) |
| SI (1) | SI2001445T1 (hr) |
| WO (1) | WO2007105016A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2516693T3 (es) * | 2006-03-16 | 2014-10-31 | Euro-Celtique S.A. | Esferoides farmacéuticos |
| AT511581A1 (de) | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | Orale retardierende formulierung |
| FR3080278B1 (fr) * | 2018-04-11 | 2021-04-30 | Ghs Patents Ltd | Procede de fabrication d'un spheroide de cannabidiol |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2471784A1 (fr) * | 1979-12-21 | 1981-06-26 | Roussel Uclaf | Medicaments antiarythmiques a action prolongee dont le principe actif est le a/2-/bis (1-methylethyl) amino/ethyl/-a-phenyl-2-pyridine acetamide ou ses sels, ainsi que le procede de preparation de ces nouveaux medicaments et compositions les renfermant |
| GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
| SE9200858L (sv) * | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Metod för framställning av pellets med fördröjd frisättning |
| DE69429710T2 (de) * | 1993-11-23 | 2002-08-08 | Euro Celtique Sa | Verfahren zur Herstellung einer Arzneizusammensetzung mit verzögerter Wirkstoffabgabe |
| DE4415921A1 (de) | 1994-05-05 | 1995-11-09 | Bayerische Motoren Werke Ag | Vorrichtung zum Dämpfen von Schwingungen in einer Getriebeschaltvorrichtung für Fahrzeuge |
| WO1995033446A1 (en) | 1994-06-03 | 1995-12-14 | The Procter & Gamble Company | Fast dissolving dosage forms |
| US5458823A (en) | 1994-10-28 | 1995-10-17 | Fuisz Technologies Ltd. | Method and apparatus for spinning feedstock material |
| JP3893439B2 (ja) * | 1994-12-19 | 2007-03-14 | 第一製薬株式会社 | 徐放性粒状製剤およびその製造方法 |
| KR100404293B1 (ko) * | 1995-05-02 | 2004-02-18 | 다이쇼 세이야꾸 가부시끼가이샤 | 경구투여용조성물 |
| US6217910B1 (en) | 1995-07-21 | 2001-04-17 | Daiichi Pharmaceutical Co., Ltd. | Granular preparation and producing process thereof |
| JP5042447B2 (ja) * | 1995-07-21 | 2012-10-03 | 第一三共株式会社 | 混合製剤 |
| US5851454A (en) | 1997-06-13 | 1998-12-22 | Fuisz Technologies, Ltd. | Spinner head having flow restricting inserts |
| RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
| US6117452A (en) | 1998-08-12 | 2000-09-12 | Fuisz Technologies Ltd. | Fatty ester combinations |
| KR100768034B1 (ko) | 1999-03-17 | 2007-10-17 | 다이이찌 세이야꾸 가부시기가이샤 | 의약 조성물 |
| US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| KR20040058103A (ko) * | 2001-02-13 | 2004-07-03 | 아스트라제네카 아베 | 신규 개질 방출 제제 |
| JP2006516969A (ja) | 2003-01-23 | 2006-07-13 | アモレパシフィック コーポレーション | 徐放性製剤及びその製造方法 |
| EP1624859A4 (en) * | 2003-05-06 | 2010-06-23 | Bpsi Holdings Inc | METHOD FOR PRODUCING THERMOFORMED COMPOSITIONS WITH ACRYLIC POLYMER BINDERS, PHARMACEUTICAL DOSAGE FORMS, AND METHOD FOR THE PRODUCTION THEREOF |
| ES2516693T3 (es) * | 2006-03-16 | 2014-10-31 | Euro-Celtique S.A. | Esferoides farmacéuticos |
-
2007
- 2007-03-16 ES ES07733554.5T patent/ES2516693T3/es active Active
- 2007-03-16 RS RS20140561A patent/RS53624B1/en unknown
- 2007-03-16 PL PL07733554T patent/PL2001445T3/pl unknown
- 2007-03-16 DK DK07733554.5T patent/DK2001445T3/da active
- 2007-03-16 US US12/225,228 patent/US9034373B2/en not_active Expired - Fee Related
- 2007-03-16 WO PCT/GB2007/050129 patent/WO2007105016A1/en active Application Filing
- 2007-03-16 JP JP2008558914A patent/JP5443768B2/ja not_active Expired - Fee Related
- 2007-03-16 PT PT77335545T patent/PT2001445E/pt unknown
- 2007-03-16 SI SI200731538T patent/SI2001445T1/sl unknown
- 2007-03-16 EP EP07733554.5A patent/EP2001445B1/en active Active
- 2007-03-16 ME MEP-2014-561A patent/ME02135B/me unknown
-
2013
- 2013-09-09 JP JP2013186621A patent/JP2014088363A/ja active Pending
-
2014
- 2014-10-15 CY CY20141100847T patent/CY1115770T1/el unknown
- 2014-10-20 HR HRP20141001TT patent/HRP20141001T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2001445T3 (pl) | 2015-06-30 |
| EP2001445B1 (en) | 2014-07-23 |
| ME02135B (me) | 2015-04-30 |
| US9034373B2 (en) | 2015-05-19 |
| JP2009530258A (ja) | 2009-08-27 |
| WO2007105016A1 (en) | 2007-09-20 |
| RS53624B1 (en) | 2015-04-30 |
| DK2001445T3 (da) | 2014-10-27 |
| JP2014088363A (ja) | 2014-05-15 |
| ES2516693T3 (es) | 2014-10-31 |
| PT2001445E (pt) | 2014-10-24 |
| JP5443768B2 (ja) | 2014-03-19 |
| US20100047337A1 (en) | 2010-02-25 |
| CY1115770T1 (el) | 2017-01-25 |
| EP2001445A1 (en) | 2008-12-17 |
| SI2001445T1 (sl) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003234395B2 (en) | Abuse-resistant opioid solid dosage form | |
| CA2519556A1 (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same | |
| CA2541371C (en) | Extended release formulations of opioids and method of use thereof | |
| HRP20100289T1 (hr) | Proizvodi otporni na miješanje za opioidnu primjenu | |
| CA2652981A1 (en) | Robust sustained release formulations | |
| JP2006524261A5 (hr) | ||
| SI1551372T1 (en) | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES | |
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| AU2017204639A1 (en) | Pharmaceutical composition comprising opioid agonist and sequestered antagonist | |
| US20050020613A1 (en) | Sustained release opioid formulations and method of use | |
| US20040110781A1 (en) | Pharmaceutical compositions containing indistinguishable drug components | |
| RU2009101082A (ru) | Фармацевтические композиции | |
| CA2557839A1 (en) | Tamper resistant dosage form comprising an adsorbent and an adverse agent | |
| HRP20120641T1 (hr) | Oralni farmaceutski oblici doziranja otporni na neovlašteno korištenje koji sadrže opioidni analgetik | |
| CA2640339A1 (en) | Tamper resistant opioid dosage forms | |
| US20130072514A1 (en) | Sustained-Release Opioid Formulations and Methods of Use | |
| CA2456601A1 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent | |
| JP2008528534A5 (hr) | ||
| JP2006524249A5 (hr) | ||
| JP2009541320A5 (hr) | ||
| ZA200700620B (en) | Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax° | |
| HRP20210973T1 (hr) | Farmaceutske kompozicije otporne na zlouporabu | |
| HRP20141001T1 (hr) | Farmaceutski sferoidi | |
| AU2018232854B2 (en) | Novel dosage form | |
| JP2021500316A5 (hr) |